In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for heart failure (HF) progression with hs-cTn methods.

Clerico, A., Zaninotto, M., Passino, C., Aspromonte, N., Piepoli, M.f., Migliardi, M., et al. (2021). Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 59(1), 79-90 [10.1515/cclm-2020-0310].

Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

Perrone M.;Fortunato A.;
2021-07-21

Abstract

In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for heart failure (HF) progression with hs-cTn methods.
21-lug-2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/11
Settore M-EDF/01
Settore BIO/12
English
cardiac natriuretic peptides
cardiac troponins
cardiovascular risk
high-sensitivity immunoassay
quality specification
reference population
Clerico, A., Zaninotto, M., Passino, C., Aspromonte, N., Piepoli, M.f., Migliardi, M., et al. (2021). Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 59(1), 79-90 [10.1515/cclm-2020-0310].
Clerico, A; Zaninotto, M; Passino, C; Aspromonte, N; Piepoli, Mf; Migliardi, M; Perrone, M; Fortunato, A; Padoan, A; Testa, A; Dellarole, F; Trenti, T...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/352668
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 44
social impact